851883-08-4

Usage

Uses

Used in Organic Synthesis:
3,4-Diaminophenylboronic acid pinacol ester is used as a reagent in the synthesis of various organic compounds for its ability to form stable complexes with diols, facilitating the development of new bioactive molecules.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 3,4-diaminophenylboronic acid pinacol ester is used as a key intermediate in the production of drugs, leveraging its reactivity and complex-forming properties to enhance drug design and synthesis.
Used in Agrochemical Production:
3,4-Diaminophenylboronic acid pinacol ester is employed as a component in the synthesis of agrochemicals, contributing to the development of effective and targeted pest control agents.
Used in Oncology Research:
3,4-Diaminophenylboronic acid pinacol ester is studied for its potential to inhibit the growth of cancer cells, making it a promising candidate for further research in oncology, with the aim of discovering new anticancer agents.
Used in Drug Delivery Systems:
3,4-DIAMINOPHENYLBORONIC ACID, PINACOL ESTER may also be utilized in the development of drug delivery systems, where its ability to form stable complexes could improve the targeting and efficacy of therapeutic agents, particularly in the treatment of cancer.

InChI:InChI=1S/C12H19BN2O2/c1-11(2)12(3,4)17-13(16-11)8-5-6-9(14)10(15)7-8/h5-7H,14-15H2,1-4H3

Upstream product

• 1075719-78-6 2-(3,4-dibromophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 875-51-4 4-Bromo-2-nitroaniline 
• 73183-34-3 bis(pinacol)diborane 
• 849236-22-2 2-nitro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 833486-94-5 4-amino-3-nitrophenylboronic acid pinacol ester 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Downstream Products

• 710348-69-9 5-(4,4,5,5-tetramethyl-1 ,3,2-dioxaborolan-2-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one 
• 863328-18-1 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3H-benzo[d]imidazol-2-amine 
• 863328-18-1 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-amine 
• 1235451-59-8 ethyl 2-(((2-(3,4-diaminophenyl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)(methyl)amino)pyrimidine-5-carboxylate 

Relevant academic research and scientific papers

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to compounds for inhibiting IL-17A and application of the compounds serving as the immunomodulator in preparation of drugs. The invention discloses an application of a compound shown as a formula I or a stereoisomer thereof in preparing medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Immunomodulator

The invention discloses an immunomodulator, and particularly relates to compounds for inhibiting IL17A and application of the compounds serving as the immunomodulator in preparation of drugs. The invention discloses an application of a compound shown as a formula I or a stereoisomer thereof in preparing medicines for inhibiting IL-17A, and provides a new choice for clinically screening and/or preparing medicines for treating diseases related to IL-17A activity.

Discovery of BAY-985, a Highly Selective TBK1/IKK? Inhibitor

The serine/threonine kinase TBK1 (TANK-binding kinase 1) and its homologue IKK? are noncanonical members of the inhibitor of the nuclear factor κB (IκB) kinase family. These kinases play important roles in multiple cellular pathways and, in particular, in inflammation. Herein, we describe our investigations on a family of benzimidazoles and the identification of the potent and highly selective TBK1/IKK? inhibitor BAY-985. BAY-985 inhibits the cellular phosphorylation of interferon regulatory factor 3 and displays antiproliferative efficacy in the melanoma cell line SK-MEL-2 but showed only weak antitumor activity in the SK-MEL-2 human melanoma xenograft model.

An organic electroluminescent compounds (by machine translation)

The present invention discloses an organic electroluminescent compounds, such as the formula (I) with or (II) the structure of the shown: Wherein A and Z is independently N or CH; R1 And R2 Are each independently selected from: H, alkyl, cycloalkyl, alkoxy, aromatic, heterocyclic aromatic; R3 - R6 Are each independently selected from: H, cyano, alkyl, cycloalkyl, alkoxy, aromatic, heterocyclic aromatic; R7 And R8 And they are connected together constitute N carbazolyl or C1 - C8 alkyl substituted carbazole-based. The design of the invention a series of boron organic molecule can be used as a light-emitting material used for making the OLED device, which exhibit relatively low driving voltage, high luminous efficiency, high color purity and long service life, has applied to the prospects of AMOLED. (by machine translation)

HETEROARYLBENZIMIDAZOLE COMPOUNDS

The present invention covers heteroarylbenzimidazole compounds of general formula (I) in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative and/or inflammatory disorders, as a sole agent or in combination with other active ingredients.

IMIDAZOPYRAZINES AND PYRAZOLOPYRIMIDINES AND THEIR USE AS AMPA RECEPTOR MODULATORS

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [Formula should be inserted here] Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH ZINC BINDING MOIETY

PROBLEM TO BE SOLVED: To provide phosphoinositide 3-kinase inhibitors with a zinc binding moiety. SOLUTION: There is provided a compound represented by formula (I) in the figure. (X is S, O or the like; Y is CH, N or the like; G1 is optionally substituted N or the like; R1 and R2 are each independently H or the like; C is a substituted heterocycle or the like; B is a linear alkyl or the like; Ra and Rb together with the nitrogen atom coupled to them are morpholino or the like; G2 is an indazole ring or the like; q, r and s are independently from 0 to 1, provided that at least one of them is 1; t is from 0 to 1; n is from 0 to 4; and p is from 0 to 2.) COPYRIGHT: (C)2016,JPOandINPIT

NOVEL 3-INDOL SUBSTITUTED DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

The present invention relates to compound of Formula (I) or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula (I).